Mutations of the KRAS gene are known to be negative predictive genetic markers for EGFR targeted therapy and were significantly associated with resistance to EGFR-blocking monoclonal antibody (cetuximab) in colon cancer [27], [37]. The gene discussed is KRAS; the disease is colonic neoplasm.